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Abstract: COPD is underdiagnosed and its early assessment is problematic. It has been sug-
gested that symptomatic smokers with normal FEV1/FVC (Stage 0 COPD, GOLD criteria) can 
develop COPD in the future. Potential early biomarkers in COPD include the matrix metallo-
proteinases (MMPs). It is not yet known, whether alterations in MMP expression are associated 
with smoking alone or with the risk of developing COPD. In this cross-sectional study MMP-8, 
MMP-9 and MMP-12 were determined from induced sputum and plasma by ELISA, immunocy-
tochemistry, zymography, and/or Western blot in non-smokers (n = 32), smokers with symptoms 
(Stage 0, GOLD criteria) (n = 23) or without symptoms (n = 23). Only MMP-8 differentiated 
Stage 0 COPD from non-symptomatic smokers (p = 0.02). MMP-9 levels were signiﬁ  cantly 
elevated in the induced sputum of non-symptomatic smokers and Stage 0 COPD (p = 0.01, 
p < 0.001) compared to non-smokers, but did not differ between the two subgroups of smokers. 
MMP-12 was higher only at Stage 0 compared to non-smokers (p = 0.04). MMP-8, MMP-9 
and MMP-12 immunoreactivity was localized in macrophages and neutrophils, especially in 
smokers. MMP-8 levels correlated signiﬁ  cantly with the small airway ﬂ  ow parameters (MEF50, 
MEF25) (p = 0.005 and p = 0.0004) and markers of neutrophil activation (myeloperoxidase, 
lactoferrin). In conclusion MMP-8 may differentiate Stage 0 from healthy smokers.
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Introduction
Chronic obstructive pulmonary disease (COPD) is leading cause of death worldwide, 
it also causes signiﬁ  cant morbidity and disability (Calverley and Walker 2003). COPD 
is underdiagnosed and its early assessment is problematic. Even the early stages of 
the disease with normal lung function parameters (FEV/FVC >0.7) possess inﬂ  am-
matory changes and structural abnormalities in the airways and lung parenchyma 
(Hogg et al 2004). The current international COPD classiﬁ  cation, GOLD criteria 
(Pauwels et al 2001), takes these problems into consideration since there may be an 
apparent risk for COPD development in symptomatic smokers who have normal lung 
function parameters. The GOLD classiﬁ  cation categorizes symptomatic subjects to 
have GOLD Stage 0 COPD. The usefulness of Stage 0 in predicting COPD develop-
ment is still unclear (Vestbo and Lange 2002). However, recent studies do indicate that 
Stage 0 has importance, at least in predicting long-term mortality (Ekberg-Aronsson 
et al 2005; Mannino 2006; Stavem et al 2006). At present no biomarker has been found 
to differentiate these at-risk individuals from healthy cigarette smokers. Potential 
markers not only need to be evaluated in terms of disease development but they may 
also be implemented in smoking cessation protocols.
Biomarkers of tissue damage/remodeling in COPD include matrix metalloprotein-
ases (MMPs) (Saetta et al 2001; Shapiro 2002; Barnes 2004). MMPs are activated by 
many different factors including cigarette smoke and oxidative stress (Rajagopalan 
et al 1996; Shapiro 2002; Nelson and Melendez 2004; Kinnula 2005; Kinnula et al 2005; International Journal of COPD 2007:2(3) 370
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Rahman and Adcock 2006). Markers of oxidative stress have 
been detected not only in COPD but also in cigarette smokers 
and subjects with Stage 0 COPD (Rytila et al 2006).
Several MMPs including MMP-1, MMP-2, MMP-8, 
MMP-9 and MMP-12 are elevated both in experimental 
emphysema and human COPD, especially MMP-8, MMP-9 
and MMP-12 have been associated with COPD (Hautamaki 
et al 1997; Beeh et al 2003; Vernooy et al 2004; Culpitt et al 
2005; Demedts et al 2006; Elkington and Friedland 2006). The 
levels of these MMPs and TIMP-1 (the major endogenous in-
hibitor of MMP-8 and MMP-9) have not been earlier compared 
in non-smokers, non-symptomatic and symptomatic smokers 
(Stage 0 COPD). Knowing the effects of cigarette smoking on 
many signaling cascades, accumulation and activation of the 
inﬂ  ammatory cells, and increased oxidative stress, it is likely 
that there is some increase/activation of MMPs in chronic 
smokers without airway ﬂ  ow limitation.
Induced sputum is a validated non-invasive method 
for the assessment of airway/tissue inﬂ  ammation/injury in 
COPD (Djukanovic et al 2002). MMP-8, MMP-9, MMP-12 
and TIMP-1 (a major endogenous inhibitor of MMP-8 and 
MMP-9) were investigated in induced sputum and plasma 
samples of healthy non-symptomatic smokers with normal 
lung function parameters by GOLD criteria and patients 
with GOLD Stage 0. MMP levels were also correlated with 
the levels of induced sputum neutrophils and macrophages, 
lactoferrin, myeloperoxidase (MPO) and nitrotyrosine to 
further characterize the association between these MMPs and 
the oxidative stress and inﬂ  ammatory proﬁ  le of the lung.
Materials and methods
Subjects
This cross-sectional study population included three groups: 
non-smoking healthy controls (NS) (n = 32), non-symptom-
atic smokers (S) (n = 23, mean 24 pack-years) and symptom-
atic smokers (chronic symptoms such as cough and phlegm, 
but no airway obstruction), ie, GOLD stage 0 (n = 23, mean 
37 pack-years) (Table 1).
Of the non-smoking subjects, 20 were never-smokers 
and 12 ex-smokers (mean 15.7 pack-years) who had stopped 
smoking at least 20 years earlier. For comparison, MMPs 
and TIMP-1 were also analyzed from stable COPD patients 
(Stage I-III) (n = 10, mean 47 pack-years), (FEV1 62% of 
predicted, DLCO/VA 66% of predicted). The staging was 
based on clinical symptoms assessed with the St George’ s 
Respiratory Questionnaire, and airﬂ  ow parameters on spi-
rometry, according to the GOLD classiﬁ  cation (American 
Thoracic Society (ATS) 1995; Pauwels et al 2001). Three 
GOLD stage 0 patients had been prescribed β2-agonists and 
inhaled corticosteroid therapy. The medications of the COPD 
Stage I–III patients were as follows: 4 patients received 
β2-agonists, inhaled corticosteroid and anticholinergics; 
4 patients received β2-agonists plus inhaled corticosteroid; 
1 received β2-agonists and anticholinergics. None were re-
ceiving systemic corticosteroid therapy.
Exclusion criteria included allergies, asthma, a history of 
respiratory disease other than COPD, or respiratory infection 
less than 8 weeks before entering the study. The study was 
approved by the Ethics Committee of Helsinki University 
Hospital, Helsinki, Finland with written consent and regis-
tered (http://www.hus.ﬁ  /clinicaltrials).
Pulmonary function tests
Flow-volume spirometry was performed with a pneumo-
tachograph based spirometer connected to a computer 
(Medriko M 904, Kuopio, Finland) (Viljanen 1982). The 
pulmonary diffusing capacity for carbon monoxide (DLCO) 
and static lung volumes were measured with a single breath 
method according to the European Respiratory Society.
Sputum induction
Sputum was induced by inhalation of hypertonic saline as 
recommended by the ERS Task Force and processed for dif-
ferential counts of inﬂ  ammatory cells as previously described 
(Rytila et al 2000; Djukanovic et al 2002). Brieﬂ  y, samples 
were treated by adding an equal volume, based on the weight 
of the sample, of dithioerythritol (DTE, Sigma, Germany) or 
phosphate-buffered-saline (PBS). The supernatant was frozen 
at –80 ºC for biochemical and immunological analyses. Cell 
viability was assessed by Trypan blue in a Burker chamber. 
Table 1 Patient characteristics
Variable Non-smokers*  Smokers  Stage  0
Number 32 23  23
Age (yr)  56 (22–72)  51 (25–64)  53 (22–70)
Sex (F/M)  6/26  11/12  4/19
Pack years  15.7 (3–31)  24 (3–50)  37 (4–84)
Post bronchodilator:     
FVC % pred  101 (80–115)  97 (65–122)  87 (67–105)
FEV1 % pred  104 (81–127)  97 (63–122)  85 (62–109)
FEV1/FVC   82.8 (75–90)  81 (70–92)  79 (70–89)
MEF50% PRED  99 (3–174)  88 (38–127)  71 (35–128)
MEF25% pred  120 (33–230)  109 (45–190)  64 (16–115)
Diffusion capacity %  104 (83–138)  96 (77–118)  93 (62–132)
pred      
* This group includes 20 lifelong non-smokers and 12 ex-smokers more than 20 
years after smoking cessation.International Journal of COPD 2007:2(3) 371
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Cytocentrifuge slides were prepared by Cytospin at 450 rpm 
for 6 min. One slide from each patient was stained with 
May-Grunwald-Giemsa-staining (Merck, Germany) for cell 
differential counts. A total of 400 cells were counted from 
each slide. The samples having less than 70% of squamous 
epithelial cells were accepted for further investigations. The 
slides were frozen at –20 ºC.
MMP-8, MMP-9, MMP-12, TIMP-1, 
and lactoferrin by ELISA
MMP-8, MMP-9, TIMP-1 and lactoferrin levels in sputum 
supernatant and plasma samples were determined by com-
mercially available ELISA kits (Amersham Biosciences, 
Cardiff, UK) according to the manufacturers’ instructions. 
MMP-12 was measured in induced sputum and plasma 
samples by a custom-made ELISA, as previously described 
(Demedts et al 2006). The detection limits were: 0.032 ng/ml 
for MMP-8, 0.6 ng/ml for MMP-9, 0.05 ng/ml for MMP-12, 
1.25 ng/ml for TIMP-1 and 1.6 ng/ml for lactoferrin.
Immunocytochemical staining of the 
MMPs, TIMP, MPO and nitrotyrosine
MMP-8, MMP-9, MMP-12, TIMP-1, MPO and nitroty-
rosine were also assessed by immunocytochemistry. The 
cytospin samples were treated with Ortho Permeaﬁ  x (Ortho 
Diagnostic Systems Inc., UK). The endogenous peroxidase 
activity was blocked with 0.3% hydrogen peroxide in PBS 
and for immunostaining, Zymed ABC Histostain-Plus Kit 
was used according to the manufacturers’ protocol. The 
samples were incubated with polyclonal rabbit anti-human 
MMP-8 (Hanemaaijer et al 1997), MMP-9 (NeoMarkers, 
Fremont, CA), TIMP-1 (Chemicon, Temecula, CA, USA), 
MPO (LabVision Corp., Fremont, US) or nitrotyrosine 
(Upstate Lake Placid, NY, USA) or monoclonal MMP-12 
(R&D Systems Inc., Minneapolis, US) antibody, and negative 
control samples with Zymed Rabbit or Mouse (MMP-12) 
isotype Control and PBS overnight at 4 ºC, and stained with 
AEC (Zymed Laboratories Inc., South San Francisco, CA) 
and thereafter with Mayer’s hematoxylin. MMP-8-, MMP-9-, 
MMP-12-, TIMP-1-, MPO- and nitrotyrosine positive and 
negative cells were counted (400 cells/cytospin).
MMP-9 by zymography and Western 
blot analysis
Sputum supernatant (60 μg protein) was incubated with 
Laemmli’s sample running buffer. After electrophoresis on 
8% sodium dodecyl sulphate-polyacrylamide gels (SDS-
PAGE) containing 1 mg/ml gelatine (Sigma, St. Louis, MO, 
USA), as a substrate, the gels were processed and stained with 
0.1% Coomassie Brilliant Blue R250 as described (Sorsa et al 
1997) for the detection of 92 kD MMP-9 (gelatinase B).
For the Western blot analysis, sputum supernatants 
were lyophilized (total protein content 40 μg per well in 
15 μL volume). After 12% SDS-PAGE, the loaded sam-
ples were electrotransferred to nitrocellulose membranes 
(Schleicher & Shuell, Dassel, Germany). The membranes 
were first incubated with polyclonal rabbit anti-human 
MMP-9 (Calbiochem, Darmstadt, Germany) and after wash-
ing with 0.1% TTBS, treated with the secondary antibody 
(Jackson ImmunoResearch Laboratories, Inc, West Grove, 
PA). The membranes were developed and quantiﬁ  ed for 
MMP-9 by the Bio-Rad Model GS-700 Imaging Densitom-
eter and AnalystTM program (Sorsa et al 1997).
Statistical analysis
All statistical analyses were performed with the SPSS 10.0 
software program (SPSS Inc., Chicago, IL, USA). As the data 
were not normally distributed, non-parametric tests were used 
for all comparisons. Data for individual variables from the 
several groups were ﬁ  rst analyzed by the Kruskal-Wallis test 
followed by the Mann-Whitney U-test. Correlations between 
variables were determined with the Spearman rank correlation 
coefﬁ  cient. A p-value of <0.05 was considered signiﬁ  cant.
Results
Lung function characteristics 
of non-smokers, healthy smokers and 
subjects with Stage 0 COPD
Lung function characteristics of the subjects are shown in 
Table 1. All the subjects had normal airway function ac-
cording to GOLD criteria (post bronchodilator FEV1/FVC 
>0.7). The cell proﬁ  le of the induced sputum specimens in 
Figure 1 reveals the greater percentage of neutrophils and 
the lower percentage of macrophages in symptomatic smok-
ers (Stage 0) than in non-smokers. Asymptomatic smokers 
and Stage 0 exhibited a higher total number of neutrophils 
(p = 0.005 and p = 0.001) than non-smokers.
The levels of MMPs and TIMP-1 
in the induced sputum and plasma 
samples by ELISA
Subjects with Stage 0 COPD had higher sputum MMP-8 
levels than the non-symptomatic smokers and non-smokers 
(p = 0.02 and p < 0.0001, Figure 2A). MMP-9 was higher in International Journal of COPD 2007:2(3) 372
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Stage 0 and non-symptomatic smokers than in non-smok-
ers (p < 0.0001 and p = 0.01), but no signiﬁ  cant difference 
existed between non-symptomatic smokers and those at Stage 
0 (p = 0.062, Figure 2B). Stage 0 patients had higher MMP-12 
than non-smokers (p = 0.04), but the difference between non-
symptomatic smokers and Stage 0 patients was not signiﬁ  cant 
(p = 0.14, Figure 2C) There were no differences in TIMP-1 
levels between the subgroups (Figure 2D).
To conﬁ  rm earlier ﬁ  ndings on the elevation of MMP-8 
and MMP-9 in COPD, their levels were also determined by 
ELISA in the induced sputum of Stage I–III COPD patients 
(n = 10). MMP-8 and -9 were signiﬁ  cantly elevated in COPD 
compared to healthy smokers (MMP-8: p < 0.0001; MMP-9: 
p = 0.01). We also recently found this to be the case with 
MMP-12 (Demedts et al 2006).
Plasma MMP-8 levels did not differ between the sub-
groups (p = 0.225). Plasma MMP-9 concentrations of 
smokers were higher than those of non-smokers (p = 0.04), 
but the difference between smokers without or with symp-
toms (Stage 0) was not signiﬁ  cant (p = 0.62). Plasma MMP-
12 levels were signiﬁ  cantly higher in Stage 0 patients when 
compared to the non-symptomatic smokers and non-smokers 
(p = 0.008). Plasma TIMP-1 levels between the subgroups 
did not differ.
Localisation of MMPs and TIMP-1 in the 
alveolar macrophages and neutrophils
MMP-8, MMP-9 and TIMP-1 were localized in the neutro-
phils and macrophages. MMP-12 was mainly detected in the 
macrophages but could also be found in some neutrophils 
(Figure 3). Some ciliated epithelial cells exhibited weak 
MMP-8 and TIMP-1 immunoreactivity. Generally, the 
reactivity was similar in healthy smokers and those at Stage 
0, whereas the expression in non-smokers was very weak 
(data not shown).
Detection of active MMP-9 by 
zymography and Western blotting
ELISA detected similar MMP-9 levels in healthy smokers 
and Stage 0 with individual variation. Therefore MMP-9 
was also evaluated by zymography and Western blotting. 
However, even these methods exhibited extensive variability. 
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Figure 1 Cell differential counts in induced sputum from non-smokers, smokers and Stage 0. Stage 0 patients had signiﬁ  cantly higher percentage of neutrophils and eosino-
phils, and lower percentage of macrophages than non-smokers. There were no differences between asymptomatic smokers and Stage 0.International Journal of COPD 2007:2(3) 373
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Figure 2 MMP-8 (A), MMP-9 (B), MMP-12 (C) and TIMP-1 (D) levels by ELISA in the induced sputum from non-smokers, asymptomatic smokers and GOLD Stage 0. 
Mean values are shown with horizontal bars. The levels of MMP-8 were increased in Stage 0 when compared with asymptomatic smokers (p = 0.02) and non-smokers (p 
< 0.0001). The levels of MMP-9 were higher in Stage 0 (p < 0.0001) and asymptomatic smokers (p = 0.01) than in non-smokers. The MMP-12 levels were higher in Stage 0 
than in non-smokers (p = 0.04) and there were no signiﬁ  cant differences in TIMP-1 levels between the groups.
Figure 3 Immunocytochemistry for MMP-8 (A), MMP-9 (B), MMP-12 (C) and TIMP-1 (D) on the cytospins of induced sputum cells from a GOLD Stage 0 smokers. Clear 
immunoreactivity for each MMP was detectable in macrophages and neutrophils from all patient groups, especially from smokers and those at GOLD Stage 0.International Journal of COPD 2007:2(3) 374
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Figure 4 Zymography and Western blotting analysis of MMP-9 in the sputum specimens. Representative zymography of 11 specimens (A): Gelatinolytic activity at 92 kD 
(pro-MMP-9) and 77–82 kD (activated MMP-9) of non-smoking controls (lanes 1–3), cigarette smokers (lanes 4–7), and subjects at GOLD stage 0 (lanes 8–11). Individual 
variation occurred, but generally MMP-9 was activated in smokers and especially those at GOLD Stage 0. Representative Western blotting of 6 specimens (B): HC healthy 
non-smoking control (lanes 1–2), HS healthy smoker (lanes 3–4), St 0 Stage 0 (lanes 5–6). There was individual variation, when calculated from 16 specimens no signiﬁ  cant 
differences between the groups could be seen. Molecular weight standards at the left.
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Zymography revealed MMP-9 gelatinolytic activity (92 kD 
pro-MMP-9 and 77–82 kD active MMP-9) both in healthy 
smokers and those at Stage 0 with no major difference be-
tween the groups (Figure 4A). MMP-9 activation has been 
assessed also from the bands obtained from Western blot 
analysis (Sorsa et al 1997). The present results by densitom-
etry were, however, variable (14% increase in the suggested 
MMP-9 active form in smokers compared to the non-smok-
ers, n = 16) (n.s.) (Figure 4B).
MMP/TIMP ratios in the sputum 
and plasma
No difference was found in the MMP-8/TIMP-1, MMP-9/
TIMP-1 or MMP-12/TIMP-1 ratios in the induced sputum of 
Stage 0, smokers and non-smokers. In contrast, the MMP-8/
TIMP-1 and MMP-9/TIMP-1 ratio in plasma was substantially 
higher in healthy smokers when compared to non-smokers 
(p = 0.009 and p = 0.02). Patients with Stage 0 had a higher 
MMP-12/TIMP-1 ratio in plasma than non-symptomatic 
smokers and non-smokers (p = 0.04 and p = 0.005).
Correlation of MMPs and TIMP-1 with 
inﬂ  ammatory cells and markers of 
oxidative stress
MMP-8, MMP-9, MMP-12 and TIMP-1 levels in the induced 
sputum, assessed by ELISA, generally correlated positively 
with the total number and percentage of neutrophils (MMP-
8: p = 0.0001 and p = 0.0002; MMP-9: p < 0.0001 and 
p < 0.0001; MMP-12 p < 0.0001 and p = 0.129; TIMP-1: 
p = 0.002 and p = 0.004) (Figure 5). In addition, MMP-8 
and MMP-9 levels negatively correlated with the percentage 
of macrophages (p = 0.02 and p = 0.0003). MMP-12 levels 
correlated positively with the total number of macrophages 
(p = 0.008).International Journal of COPD 2007:2(3) 375
Matrix metalloproteinases and smoking
Mean lactoferrin levels in induced sputum of GOLD Stage 
0, smokers and non-smokers were 59.7 ± 18.0, 36.3 ± 11.0 
and 28.7 ± 3.42 μg/ml (p = 0.071) and in plasma 772 ± 121, 
761 ± 155 and 772 ± 121 ng/ml (p = 0.616), respectively. 
MMP-8, MMP-9 and MMP-12 correlated with sputum lac-
toferrin (Figure 6) and MMP-8 and MMP-9 correlated with 
the levels of MPO positive cells (r = 0.55, p = 0.004 and 
r = 0.49, p = 0.01) but not with nitrotyrosine.
Correlation between the levels 
of MMPs and lung function parameters
The purpose of this study was to evaluate the signiﬁ  cance of 
MMPs at the early stages of COPD with normal lung func-
tion parameters based on GOLD criteria (FEV/FVC). Special 
interest was with the airﬂ  ow parameters in the small airways 
(MEF50, MEF25). When the various MMPs were correlated 
with the lung function parameters of all smokers with or 
without COPD (GOL Stage 0) there was highly signiﬁ  cant 
correlation with all lung function parameters (Table 2).
Discussion
The present study suggests that MMP-8 can differentiate 
symptomatic smokers (Stage 0), ie, those who may be at 
risk for COPD development (Pauwels et al 2001; Willemse 
et al 2005; Mannino 2006; Stavem et al 2006) from non-
symptomatic chronic smokers. MMP-8 also correlated with 
the lung function parameters, in particular the correlations 
with the small airway ﬂ  ow parameters were highly signiﬁ  -
cant. Also MMP-9 and MMP-12 were already elevated in the 
induced sputum of Stage 0 COPD but neither MMP-9 nor 
MMP-12, with the exception of plasma MMP-12, appeared 
to differentiate healthy smokers from Stage 0 patients. MMPs 
can be activated by ROS, and this study also found a sig-
niﬁ  cant association especially between the levels of MMP-8 
I=0.50, p<0.0001 I=0.36, p=0.002
I=0.70, p<0.0001 I=0.66, p<0.0001 6
5
5
4
3
2
1
0
0 200
0 500 1000 2000 2500 3000 1500
400 600 800 1000 1200
4,5
3,5
2,5
1,5
0,5
5
4
3
2
1
4,5
3,5
2,5
1,5
0,5
4
3
2
1
0
0
0
6
5
5
4
3
2
1
10 20 15
0
100 200 300 400 500 600
Sputum MMP-8 ng/ml
Sputum MMP-12 ng/ml Sputum TIMP-1 ng/ml
Sputum MMP-9 ng/ml
S
p
u
t
u
m
 
t
o
t
a
l
 
n
e
u
t
r
o
p
h
i
l
s
 
1
0
E
6
S
p
u
t
u
m
 
t
o
t
a
l
 
n
e
u
t
r
o
p
h
i
l
s
 
1
0
E
6
S
p
u
t
u
m
 
t
o
t
a
l
 
n
e
u
t
r
o
p
h
i
l
s
 
1
0
E
6
S
p
u
t
u
m
 
t
o
t
a
l
 
n
e
u
t
r
o
p
h
i
l
s
 
1
0
E
6
A
CD
B
Figure 5 Correlation between sputum MMP-8 (A) (n = 70; r = 0.70; p < 0.0001), MMP-9 (B) (n = 69; r = 0.66; p < 0.0001), MMP-12 (C) (n = 56; r = 0.50; p < 0.0001), and 
TIMP-1 (D) (n = 68; r = 0.36; p = 0.002) levels and total number of neutrophils.International Journal of COPD 2007:2(3) 376
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and MMP-9 and neutrophils and markers of their activation 
(lactoferrin, MPO). However, as in biological samples in 
general, there was considerable individual variation in the 
levels of MMPs and TIMP-1 in both the induced sputum and 
the plasma specimens.
One problem in assessing MMPs in cigarette smokers 
has been the wide variation in the smoking history and time 
elapsed from smoking cessation of the control group (Cataldo 
et al 2000; Kang et al 2003; Culpitt et al 2005). We included a 
representative group of non-smokers and smokers, who were 
either symptom-free or exhibiting symptoms. Based on this 
study only MMP-8 could differentiate symptomatic smok-
ers from healthy chronic smokers with normal FEV1/FVC 
ie, without major airway obstruction. The levels of MMP-8, 
MMP-9 and MMP-12 in the induced sputum of ex-smok-
ers and lifelong non-smokers were similar suggesting that 
the effects of smoking on MMP-8, MMP-9 and MMP-12 
levels may be reversible. Like in many biological measure-
ments there was wide variation in MMP-values within the 
groups with some outliners in each group. These values and 
the clinical characteristics of the subjects were carefully 
re-evaluated. To conﬁ  rm the elevation of these MMPs in 
COPD as earlier published (Vernooy et al 2004; Culpitt et al 
2005; Mercer et al 2005), additional measurements were 
conducted with the sputum specimens of Stage I–III COPD 
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Figure 6 Correlation between MMP-8 (A) (n = 34; r = 0.63; p < 0.0001), MMP-9 (B) (n = 35; r = 0.50; p = 0.002) and MMP-12 (C) (n = 24; r = 0.53; p = 0.008) and lacto-
ferrin levels in induced sputum.
Table 2 Correlation between the levels of sputum MMPs and 
lung spirometric variables
Parameter MMP-8 MMP-9  MMP-12  TIMP-1
FEV1% pred  r = –0.42  r = –0.39  r = –0.32  r = –0.17
  p = 0.0007  p = 0.002  p = 0.03  p = 0.186
FVC% pred  r = –0.25  r = –0.25  r = –0.32  r = –0.03
  p = 0.05  p = 0.05  p = 0.03  p = 0.82
FEV1/FVC  r = –0.36  R = –0.36  r = –0.13  r = –0.31
  p = 0.005   p = 0.004  p = 0.36  p = 0.02
MEF50% pred  r = –0.35  R = –0.35  r = –0.27  r = –0.21
  p = 0.005  p = 0.005  p = 0.06  p = 0.09
MEF25% pred  r = –0.44  R = –0.46  r = –0.3  r = –0.16
  p = 0.0004  p = 0.0003  p = 0.04  p = 0.22International Journal of COPD 2007:2(3) 377
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patients (Demedts et al 2006), detecting signiﬁ  cantly higher 
levels of these MMPs in COPD subjects in comparison to 
healthy smokers.
Some previous studies have shown MMP-9 elevation in 
chronic cigarette smokers when compared to non-smokers 
(Lim et al 2000; Kang et al 2003), but no comparisons were 
made between asymptomatic and symptomatic smokers. 
Our recent study found higher MMP-12 levels in the in-
duced sputum of COPD patients when compared to smokers 
and non-smokers (Demedts et al 2006), but again non-
symptomatic and symptomatic smokers were not compared. 
Our present results with MMP-8 and Stage 0 are in line with 
previous suggestions about the special role of MMP-8 in 
the development of emphysema (Segura-Valdez et al 2000). 
Since MMP-9 levels as assessed by ELISA were very similar 
both in non-symptomatic smokers and individuals at Stage 
0, its activation was further investigated by zymography 
and Western blot analysis which showed extensive inter-
individual variability. MMP-12 levels were higher in 
patients with Stage 0 than in non-smokers but there was 
no difference between healthy smokers and individuals 
at Stage 0. Also MMP-12 showed high variability in the 
Western blotting analysis (not shown). This does not sig-
nify that MMP-12 has no relevance in COPD development 
(Russell et al 2002b; Demedts et al 2006), but the fact that 
MMP-12 is already increased in smokers without airway 
obstruction.
MMP-8, MMP-9 and MMP-12 are known to be expressed 
in alveolar macrophages (Russell et al 2002a; Vernooy et al 
2004; Bracke et al 2005; Molet et al 2005) and MMP-8 and 
MMP-9 in neutrophils (Cataldo et al 2001; Barnes et al 2003; 
Beeh et al 2003; Takafuji et al 2003; Vernooy et al 2004; 
Culpitt et al 2005; Gueders et al 2005). These previous obser-
vations were conﬁ  rmed here and the expressions were similar 
in healthy and symptomatic smokers. Although MMP-12 
is produced by macrophages, its presence or absence in 
neutrophils has not been reported (Churg et al 2003; Bracke 
et al 2005; Molet et al 2005). In the present study some 
neutrophils clearly exhibited MMP-12 immunoreactivity. 
The relative functional role of alveolar macrophages and 
neutrophils as cellular sources of these MMPs in COPD is 
still unclear. The present ﬁ  ndings support the importance 
of neutrophils as all MMPs correlated with neutrophils and 
markers of neutrophil activation.
MMPs were also elevated in the plasma of smokers, in 
agreement with previous observations (Nakamura et al 1998) 
and with the fact that COPD is a systemic disease, but also 
with the fact that MMPs are associated with other smoking-
related systemic diseases (Jones et al 2003; MacCallum 2005; 
Wouters 2005). This is the ﬁ  rst study to report the elevated 
plasma MMP-12 levels in symptomatic smokers, but the 
relative role of all of these MMPs as systemic markers in 
COPD progression remains to be clariﬁ  ed.
TIMP-1 is a major endogenous inhibitor of MMP-8 
and -9 and shown to be elevated in COPD (Beeh et al 2003; 
Owen et al 2003; Culpitt et al 2005; Higashimoto et al 2005). 
The sputum MMP-8/TIMP-1 and MMP-9/TIMP-1 ratio did 
not change signiﬁ  cantly in smokers, pointing to a role for 
TIMP-1 as a natural defense mechanism in preventing tissue 
destruction.
The conformation of latent MMPs is maintained by thiol 
interactions between Cys-residues in the prodomain and the 
zinc atom present in the catalytic site of all MMPs. Disrup-
tion of this interaction is thought to represent the critical 
step in initiating the process of MMP autoactivation. ROS 
are known to reversibly react with -SH groups, such as those 
involved in preserving MMP latency (Rajagopalan et al 
1996). Recent studies from our laboratory and others have 
indicated that cigarette smoke can elevate the oxidant burden 
also in healthy humans without airway obstruction (Rytila 
et al 2006). The present study not only found increased 
levels of MMPs, especially MMP-8 in healthy smokers and 
those with symptoms (Stage 0), but also found a signiﬁ  cant 
correlation between MMP-8, MMP-9 and the levels of MPO 
and lactoferrin, both of which are neutrophil-derived mark-
ers of oxidant generation. These ﬁ  ndings further support the 
hypothesis that especially neutrophil derived oxidants, may 
signiﬁ  cantly activate/induce the tissue destructive MMPs 
already in the lungs of healthy cigarette smokers. We did not 
ﬁ  nd any association between MMPs and nitrotyrosine immu-
noreactivity showing also the complexity between smoking, 
oxidative stress and the expression of oxidized/nitrosylated 
proteins in sputum inﬂ  ammatory cells.
In conclusion, MMPs, especially MMP-8, may func-
tion as sensitive biomarkers in COPD development. The 
relative role of various MMPs as markers of COPD and its 
progression remains to be clariﬁ  ed in future longitudinal 
investigations.
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